Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "tangenX"

Looking for quality documents?
corporate icon
Configurators
• OPUS Configurators • TangenX Configurator • Large System Configurator • Find a KrosFlo System • Find a Hollow Fiber • Find a Dialysis Device • Fluid Management Custom Showcase
news icon
Repligen acquires TangenX Technology Corporation
news icon
Repligen adds single-use filtration technology through TangenX acquisition
news icon
Repligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF Device
Repligen Corporation yoday announced the commercial launch of TangenX® SC, the industry’s first holder-free, self-contained Tangential Flow Filtration (TFF) device.The technology is especially suited to the manufacture of biologics where fully closed systems are critical or ideal.
publications icon
Rapid, Simple, and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors at Scale
publications icon
Economic Impact of Adopting Single-use TFF Flat Sheet Cassettes
publications icon
Evaluation and Comparison of Tangential Flow Filtration Cassettes for Use in a Monoclonal Antibody Purification Process
external link icon
Repligen to Participate in 14th Annual Craig-Hallum Institutional Investor Conference
WALTHAM, Mass., May 24, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that management will participate in the 14 th Annual Craig-Hallum Institutional Investor Conference, to be held in Minneapolis on Wednesday, May 31, 2017.
About Repligen Corporation Repligen Corporation (NASDAQ:RGEN) is a bioprocessing company focused on the development, manufacture and commercialization of highly innovative products used to improve the biological drug manufacturing process. Our portfolio includes Protein products (Protein A affinity ligands, cell culture growth factors), Chromatography products (OPUS® pre-packed columns, chromatography resins, ELISA kits) and Filtration products (XCell™ ATF Systems, TangenX™ Sius™ TFF cassettes). Our bioprocessing products are sold to major life sciences companies, biopharmaceutical development companies and contract manufacturing
external link icon
Repligen to Present at Jefferies 2019 Healthcare Conference
WALTHAM, Mass., June 04, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that Jon K. Snodgres, Chief Financial Officer, will present at the Jefferies 2019 Global Healthcare Conference on Thursday, June 6 at 8:30 a.m. EDT.
A live audio webcast of the presentation will be accessible through the Investor Events section of the Company’s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a global bioprocessing company that develops and commercializes highly innovative products that deliver cost and process efficiencies to biological drug manufacturers worldwide. Our portfolio includes filtration products (including XCell™ ATF, TangenX™ SIUS™ TFF and Spectrum KrosFlo™ TFF filters and systems), chromatography products (OPUS®
external link icon
Repligen Reports First Quarter 2017 Financial Results
Record quarterly revenue of $30.6 million reflects 22% year-over-year growth or 24% at constant currency
Company increases net income and EPS guidance WALTHAM, Mass., May 04, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter ended March 31, 2017. Detailed in this press release are the Company's performance highlights for the quarter, followed by financial guidance for the year 2017 and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer, said, “We had a strong start to the year, reporting first quarter revenue growth of 24% at constant currency.  Our Chromatography and Filtration businesses were major drivers of growth in the quarter, with our two acquisitions from 2016 – Atoll GmbH and TangenX Technology Corporation – contributing to the overall